Literature DB >> 33434062

Biology of Disease Relapse in Myeloid Disease: Implication for Strategies to Prevent and Treat Disease Relapse After Stem-Cell Transplantation.

Joseph C Rimando1, Matthew J Christopher1, Michael P Rettig1, John F DiPersio1.   

Abstract

Entities:  

Mesh：

Year:  2021        PMID： 33434062      PMCID： PMC8462627          DOI： 10.1200/JCO.20.01587

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  144 in total

1.  Low-dose 5-azacytidine as preventive therapy for relapse of AML and MDS following allogeneic HCT.

Authors:  J El-Cheikh; R Massoud; E Fares; N Kreidieh; R Mahfouz; M Charafeddine; M A Kharfan-Dabaja; A Bazarbachi
Journal:  Bone Marrow Transplant       Date:  2017-04-03       Impact factor: 5.483

2.  Fatal GvHD induced by PD-1 inhibitor pembrolizumab in a patient with Hodgkin's lymphoma.

Authors:  A K Singh; L F Porrata; O Aljitawi; T Lin; L Shune; S Ganguly; J P McGuirk; S Abhyankar
Journal:  Bone Marrow Transplant       Date:  2016-04-25       Impact factor: 5.483

3.  Infusion of donor-derived CD8+ memory T cells for relapse following allogeneic hematopoietic cell transplantation.

Authors:  Lori Muffly; Kevin Sheehan; Randall Armstrong; Kent Jensen; Keri Tate; Andrew R Rezvani; David Miklos; Sally Arai; Judith Shizuru; Laura Johnston; Everett Meyer; Wen-Kai Weng; Ginna G Laport; Robert S Negrin; Sam Strober; Robert Lowsky
Journal:  Blood Adv       Date:  2018-03-27

4.  Prophylactic donor lymphocyte infusion after allogeneic stem cell transplantation in acute leukaemia - a matched pair analysis by the Acute Leukaemia Working Party of EBMT.

Authors:  Christoph Schmid; Myriam Labopin; Nicolaas Schaap; Hendrik Veelken; Michael Schleuning; Michael Stadler; Juergen Finke; Erin Hurst; Frederic Baron; Olle Ringden; Gesine Bug; Didier Blaise; Johanna Tischer; Adrian Bloor; Jordi Esteve; Sebastian Giebel; Bipin Savani; Norbert-Claude Gorin; Fabio Ciceri; Mohamad Mohty; Arnon Nagler
Journal:  Br J Haematol       Date:  2018-11-22       Impact factor: 6.998

5.  Outcome of patients with distinct molecular genotypes and cytogenetically normal AML after allogeneic transplantation.

Authors:  Christoph Schmid; Myriam Labopin; Gerard Socié; Etienne Daguindau; Liisa Volin; Anne Huynh; Jean Henri Bourhis; Noel Milpied; Jan Cornelissen; Patrice Chevallier; Johan Maertens; Pavel Jindra; Didier Blaise; Stig Lenhoff; Norbert Ifrah; Frédéric Baron; Fabio Ciceri; Claude Gorin; Bipin Savani; Sebastian Giebel; Emmanuelle Polge; Jordi Esteve; Arnon Nagler; Mohamad Mohty
Journal:  Blood       Date:  2015-09-08       Impact factor: 22.113

Review 6.  FLT3 inhibitors in acute myeloid leukemia: ten frequently asked questions.

Authors:  Ahmad I Antar; Zaher K Otrock; Elias Jabbour; Mohamad Mohty; Ali Bazarbachi
Journal:  Leukemia       Date:  2020-01-09       Impact factor: 11.528

7.  CD34(+) lineage specific donor cell chimerism for the diagnosis and treatment of impending relapse of AML or myelodysplastic syndrome after allo-SCT.

Authors:  F Rosenow; A Berkemeier; U Krug; C Müller-Tidow; J Gerss; G Silling; C Groth; P Wieacker; N Bogdanova; R Mesters; T Büchner; J Kienast; W E Berdel; M Stelljes
Journal:  Bone Marrow Transplant       Date:  2013-02-04       Impact factor: 5.483

8.  Risk stratification-directed donor lymphocyte infusion could reduce relapse of standard-risk acute leukemia patients after allogeneic hematopoietic stem cell transplantation.

Authors:  Chen-Hua Yan; Dai-Hong Liu; Kai-Yan Liu; Lan-Ping Xu; Yan-Rong Liu; Huan Chen; Wei Han; Yu Wang; Ya-Zhen Qin; Xiao-Jun Huang
Journal:  Blood       Date:  2012-02-14       Impact factor: 22.113

9.  Immune Escape of Relapsed AML Cells after Allogeneic Transplantation.

Authors:  Matthew J Christopher; Allegra A Petti; Michael P Rettig; Christopher A Miller; Ezhilarasi Chendamarai; Eric J Duncavage; Jeffery M Klco; Nicole M Helton; Michelle O'Laughlin; Catrina C Fronick; Robert S Fulton; Richard K Wilson; Lukas D Wartman; John S Welch; Sharon E Heath; Jack D Baty; Jacqueline E Payton; Timothy A Graubert; Daniel C Link; Matthew J Walter; Peter Westervelt; Timothy J Ley; John F DiPersio
Journal:  N Engl J Med       Date:  2018-10-31       Impact factor: 91.245

10.  Toll-like receptor 7/8-matured RNA-transduced dendritic cells as post-remission therapy in acute myeloid leukaemia: results of a phase I trial.

Authors:  Felix S Lichtenegger; Frauke M Schnorfeil; Maurine Rothe; Katrin Deiser; Torben Altmann; Veit L Bücklein; Thomas Köhnke; Christian Augsberger; Nikola P Konstandin; Karsten Spiekermann; Andreas Moosmann; Stephan Boehm; Melanie Boxberg; Mirjam Hm Heemskerk; Dennis Goerlich; Georg Wittmann; Beate Wagner; Wolfgang Hiddemann; Dolores J Schendel; Gunnar Kvalheim; Iris Bigalke; Marion Subklewe
Journal:  Clin Transl Immunology       Date:  2020-03-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.